Table 1.
Summary of demographic and laboratory data on 141 patients
| Variable* | CT with no positive findings (n = 61) | CT w positive findings (n = 80) | p value |
|---|---|---|---|
| Age (years) | 66.0 (14.2) | 62.9 (16.4) | 0.245 |
| Gender (n, % female) | 44 (72.1) | 47 (58.8) | 0.1 |
| Race (n, %) | 0.46 | ||
| Hispanic | 21 (34.4) | 35 (43.8) | |
| African American | 21 (34.4) | 28 (35.0) | |
| White | 5 (8.2) | 7 (8.8) | |
| Asian | 3 (4.9) | 2 (2.5) | |
| Other/mixed | 5 (8.2) | 6 (7.5) | |
| Unknown | 6 (9.8) | 2 (2.5) | |
| Charlson score | 1 (0 to 4) | 2 (0 to 4.5) | 0.092 |
| Death (n, %) | 5 (8.2) | 10 (12.5) | 0.412 |
| Time period between CT and death (days) | 7 (5 to 12) | 6.5 (5 to 12) | 0.902 |
| Time period between CT and COVID test (days) | 0 (0 to 0) | 0 (− 1 to 1) | 0.841 |
| CT location (n, %) | 0.582 | ||
| Emergency department | 13 (21.3) | 14 (17.5) | |
| Inpatient | 46 (75.4) | 65 (81.2) | |
| Outpatient | 2 (3.3) | 1 (1.2) | |
| No intravenous contrast administered | 3 (4.9) | 0 (0) | 0.079 |
| Thorax coverage included | 12 (19.2) | 15 (18.8) | 0.89 |
| CT findings typical or intermediate for COVID | 39 (63.9) | 40 (50.0) | 0.099 |
| Time period between CT and CMP (days)a | 0 (0 to 0) | 0 (0 to 0) | 0.698 |
| Complete metabolic profile | |||
| Sodiuma (mEq/L) | 137.9 (6.3) | 138.2 (8.0) | 0.768 |
| Potassiumb (mEq/L) | 4.3 (0.6) | 4.2 (0.6) | 0.511 |
| Chloridea (mmol/L) | 98.8 (6.5) | 99.9 (8.3) | 0.422 |
| Carbon dioxidea (mmol/L) | 22.9 (3.4) | 22.5 (4.1) | 0.534 |
| Anion gapa (mEq/L) | 16.1 (3.2) | 15.9 (4.6) | 0.746 |
| Blood urea nitrogenb (mg/dL) | 16 (11 to 22) | 17 (11 to 24) | 0.454 |
| Creatininea (mg/dL) | 0.9 (0.7 to 1.2) | 0.9 (0.7 to 1.2) | 0.988 |
| GFRa (mL/min) | 69 (47 to 91) | 71 (54 to 98) | 0.645 |
| Glucosec (mg/dL) | 127.0 (100 to 171) | 131.0 (96 to 184) | 0.826 |
| Magnesiumd (mEq/L) | 2.0 (0.3) | 1.9 (0.3) | 0.331 |
| Alkaline phosphatasee (IU/L) | 75.5 (62 to 92) | 102.5 (76 to 140) | < 0.001 |
| Aspartate aminotransferasef (IU/L) | 28 (23 to 43) | 34 (23 to 52) | 0.165 |
| Alanine aminotransferasef (IU/L) | 21.5 (15 to 32.5) | 26 (17 to 39) | 0.185 |
| Albumine (g/dL) | 4.0 (0.5) | 3.6 (0.8) | 0.014 |
| Total bilirubing (mg/dL) | 0.4 (0.3 to 0.6) | 0.6 (0.3 to 0.8) | 0.036 |
| Direct bilirubing (mg/dL) | 0.15 (0.1 to 0.2) | 0.2 (0.1 to 0.3) | 0.05 |
| Lactate dehydrogenaseh (U/L) | 354 (231 to 463) | 304 (244 to 361) | 0.43 |
| Total proteini (g/dL) | 7.2 (0.7) | 7.1 (1.1) | 0.46 |
| Amylasej (U/L) | 80 (46 to 100) | 66 (56 to 84) | 0.63 |
| Lipasek (U/L) | 32 (19 to 69) | 42 (22 to 60) | 0.63 |
| Time period between CT and CBC (days)a | 0 (0 to 0) | 0 (0 to 0) | 0.988 |
| Complete blood count | |||
| White blood cell counta (mln cells/mL) | 4.5 (4.0 to 5.2) | 4.3 (3.3 to 5.1) | 0.123 |
| Hemoglobina (g/dL) | 12.7 (2.1) | 11.5 (2.9) | 0.007 |
| Hematocrita (%) | 39.9 (6.1) | 36.4 (8.4) | 0.005 |
| Platelet counta (mln cells/mL) | 219 (156 to 283) | 212 (146.5 to 292.5) | 0.578 |
| Neutrophil (%)a | 74 (66 to 81) | 74 (62 to 82) | 0.818 |
| Lymphocyte (%)a | 14 (11 to 25) | 15.5 (9 to 23.5) | 0.676 |
| Monocyte (%)a | 8 (6 to 10) | 8 (5 to 10) | 0.538 |
| Eosinophil (%)a | 0 (0 to 1) | 0 (0 to 1) | 0.167 |
| Basophil (%)a | 0 (0 to 0) | 0 (0 to 0) | 0.635 |
| Time period between CT and coagulation profile (days)l | 0 (0 to 0) | 0 (0 to 0) | 0.727 |
| Prothrombin timef (s) | 14.0 (13.5 to 14.8) | 14.7 (13.9 to 16.2) | 0.002 |
| Partial thromboplastin timem (s) | 36.8 (27.5 to 36.8) | 31.7 (28.9 to 38.5) | 0.424 |
| International normalized ratiof | 1.1 (1.1 to 1.1) | 1.1 (1.1 to 1.3) | 0.013 |
*Reported as mean and standard deviation, unless noted otherwise
aIn 139 patients with nonmissing data
bIn 129 patients with nonmissing data
cIn 138 patients with nonmissing data
dIn 81 patients with nonmissing data
eIn 126 patients with nonmissing data
fIn 124 patients with nonmissing data
gIn 125 patients with nonmissing data
hIn 59 patients with nonmissing data
iIn 90 patients with nonmissing data
jIn 19 patients with nonmissing data
kIn 63 patients with nonmissing data
lIn 134 patients with nonmissing data
mIn 113 patients with nonmissing data